New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Total Body Irradiation Plus Etoposide Improves Survival in Select Transplant-Eligible Pediatric High-Risk ALL

Total Body Irradiation Plus Etoposide Improves Survival in Select Transplant-Eligible Pediatric High-Risk ALL

February 25, 2021Hayley VirgilTotal body irradiation plus etoposide prior to hematopoietic stem cell transplantation resulted in improved overall survival and a lower risk of relapse in pediatric pati
World medicine November 20,2023
Total Body Irradiation Plus Etoposide Improves Survival in Select Transplant-Eligible Pediatric High-Risk ALL

Total Body Irradiation Plus Etoposide Improves Survival in Select Transplant-Eligible Pediatric High-Risk ALL

February 25, 2021Hayley VirgilTotal body irradiation plus etoposide prior to hematopoietic stem cell transplantation resulted in improved overall survival and a lower risk of relapse in pediatric pati
World medicine November 20,2023
Intensified Daratumumab Plus CVRd and Bortezomib-Augmented ASCT Demonstrates Promise in Ultra High–Risk Multiple Myeloma

Intensified Daratumumab Plus CVRd and Bortezomib-Augmented ASCT Demonstrates Promise in Ultra High–Risk Multiple Myeloma

June 11, 2021Audrey SternbergIntensified induction therapy with daratumumab in addition to cyclophosphamide, bortezomib, lenalidomide, and dexamethasone and bortezomib-augmented autologous stem cell t
World medicine November 20,2023
Intensified Daratumumab Plus CVRd and Bortezomib-Augmented ASCT Demonstrates Promise in Ultra High–Risk Multiple Myeloma

Intensified Daratumumab Plus CVRd and Bortezomib-Augmented ASCT Demonstrates Promise in Ultra High–Risk Multiple Myeloma

June 11, 2021Audrey SternbergIntensified induction therapy with daratumumab in addition to cyclophosphamide, bortezomib, lenalidomide, and dexamethasone and bortezomib-augmented autologous stem cell t
World medicine November 20,2023
Matched Sibling Donor Transplant Shows Improved OS at 2 Years in Relapsed/Refractory ALL

Matched Sibling Donor Transplant Shows Improved OS at 2 Years in Relapsed/Refractory ALL

April 26, 2022Gina MauroPatients with relapsed/refractory acute lymphoblastic leukemia who underwent matched sibling donor transplants had a significantly higher overall survival at 2 years compared w
World medicine November 20,2023
Matched Sibling Donor Transplant Shows Improved OS at 2 Years in Relapsed/Refractory ALL

Matched Sibling Donor Transplant Shows Improved OS at 2 Years in Relapsed/Refractory ALL

April 26, 2022Gina MauroPatients with relapsed/refractory acute lymphoblastic leukemia who underwent matched sibling donor transplants had a significantly higher overall survival at 2 years compared w
World medicine November 20,2023
Stem Cell Recipients Develop Robust Immunity Against SARS-CoV2 and Common Human Coronaviruses

Stem Cell Recipients Develop Robust Immunity Against SARS-CoV2 and Common Human Coronaviruses

February 8, 2021Kristie L. KahlFebruary 8, 2021 - These findings may have implications for patients with hematologic malignancies, suggesting the development of protective memory against SARS-CoV2 and
World medicine November 20,2023
Stem Cell Recipients Develop Robust Immunity Against SARS-CoV2 and Common Human Coronaviruses

Stem Cell Recipients Develop Robust Immunity Against SARS-CoV2 and Common Human Coronaviruses

February 8, 2021Kristie L. KahlFebruary 8, 2021 - These findings may have implications for patients with hematologic malignancies, suggesting the development of protective memory against SARS-CoV2 and
World medicine November 20,2023
Improved Induction Therapies Could Eliminate the Need for Transplant in Myeloma

Improved Induction Therapies Could Eliminate the Need for Transplant in Myeloma

September 16, 2020Hayley VirgilJeffrey Wolf, MD, discusses how induction therapies continue to improve the depth of response in patients with multiple myeloma and how it may be possible to eliminate t
World medicine November 20,2023
Improved Induction Therapies Could Eliminate the Need for Transplant in Myeloma

Improved Induction Therapies Could Eliminate the Need for Transplant in Myeloma

September 16, 2020Hayley VirgilJeffrey Wolf, MD, discusses how induction therapies continue to improve the depth of response in patients with multiple myeloma and how it may be possible to eliminate t
World medicine November 20,2023
Maintenance Daratumumab Improves PFS in Newly Diagnosed Transplant-Eligible Myeloma

Maintenance Daratumumab Improves PFS in Newly Diagnosed Transplant-Eligible Myeloma

October 22, 2020Gina MauroSingle-agent daratumumab as maintenance therapy improved progression-free survival compared with observation in patients with newly diagnosed multiple myeloma eligible for au
World medicine November 20,2023
Maintenance Daratumumab Improves PFS in Newly Diagnosed Transplant-Eligible Myeloma

Maintenance Daratumumab Improves PFS in Newly Diagnosed Transplant-Eligible Myeloma

October 22, 2020Gina MauroSingle-agent daratumumab as maintenance therapy improved progression-free survival compared with observation in patients with newly diagnosed multiple myeloma eligible for au
World medicine November 20,2023
Daratumumab Consolidation Appears Safe, Shows Encouraging Efficacy in Very Good Responders With Myeloma

Daratumumab Consolidation Appears Safe, Shows Encouraging Efficacy in Very Good Responders With Myeloma

April 9, 2021Kristi RosaDaratumumab appears to be safe when used as consolidation therapy in patients with multiple myeloma, even soon after autologous stem cell transplant, and the agent has also dem
World medicine November 20,2023
Daratumumab Consolidation Appears Safe, Shows Encouraging Efficacy in Very Good Responders With Myeloma

Daratumumab Consolidation Appears Safe, Shows Encouraging Efficacy in Very Good Responders With Myeloma

April 9, 2021Kristi RosaDaratumumab appears to be safe when used as consolidation therapy in patients with multiple myeloma, even soon after autologous stem cell transplant, and the agent has also dem
World medicine November 20,2023
Abatacept Reduces Graft Vs Host Disease, Prednisone Use Following Stem Cell Transplant

Abatacept Reduces Graft Vs Host Disease, Prednisone Use Following Stem Cell Transplant

April 24, 2022Jason HarrisAbatacept significantly reduced steroid-refractory chronic graft versus host disease and the use of prednisone following allogeneic hematopoietic stem cell transplantation.Ab
World medicine November 20,2023
Abatacept Reduces Graft Vs Host Disease, Prednisone Use Following Stem Cell Transplant

Abatacept Reduces Graft Vs Host Disease, Prednisone Use Following Stem Cell Transplant

April 24, 2022Jason HarrisAbatacept significantly reduced steroid-refractory chronic graft versus host disease and the use of prednisone following allogeneic hematopoietic stem cell transplantation.Ab
World medicine November 20,2023
Tisagenlecleucel Fails to Improve EFS in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Tisagenlecleucel Fails to Improve EFS in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

December 14, 2021Jessica HergertAs second-line treatment, tisagenlecleucel failed to demonstrate an event-free survival advantage compared with standard of care platinum-based chemotherapy followed by
World medicine November 20,2023
Tisagenlecleucel Fails to Improve EFS in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Tisagenlecleucel Fails to Improve EFS in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

December 14, 2021Jessica HergertAs second-line treatment, tisagenlecleucel failed to demonstrate an event-free survival advantage compared with standard of care platinum-based chemotherapy followed by
World medicine November 20,2023
Orca-T Graft Improves Outcomes in Myelofibrosis Following Allogeneic Stem Cell Transplant

Orca-T Graft Improves Outcomes in Myelofibrosis Following Allogeneic Stem Cell Transplant

February 4, 2022Gina MauroArpita Gandhi, MD, discusses a subgroup analysis of patients with myelofibrosis who received Orca-T and how this type of therapy could be a game-changer for this patient popu
World medicine November 20,2023
Orca-T Graft Improves Outcomes in Myelofibrosis Following Allogeneic Stem Cell Transplant

Orca-T Graft Improves Outcomes in Myelofibrosis Following Allogeneic Stem Cell Transplant

February 4, 2022Gina MauroArpita Gandhi, MD, discusses a subgroup analysis of patients with myelofibrosis who received Orca-T and how this type of therapy could be a game-changer for this patient popu
World medicine November 20,2023
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com